W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Decision
P/0061/2021 : EMA decision of 12 February 2021 on the granting of a product specific waiver for recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107) (EMEA-002884-PIP01-20)